- |||||||||| ALN-VSP / Alnylam, refanezumab (GSK249320) / GSK
Review, Journal: Advances in Antibody-Based Therapeutics for Cerebral Ischemia. (Pubmed Central) - Jan 22, 2023
In this article, we review the current antibody-based pharmaceuticals for neurological diseases, the use of antibody drugs in stroke, strategies to improve the efficacy of antibody therapeutics in cerebral ischemia, and the recent advancement of antibody drugs in clinical practice. Overall, we highlight the need of enhancing blood-brain barrier (BBB) penetration for the improvement of antibody-based therapeutics in the brain, which could greatly enhance the antibody medications for cerebral ischemia in clinical practice.
|
